Okay,here’s a verification of the claims made in the Antengene press release,using web searches as of today,January 16,2026. I’ll break it down section by section, noting confirmations, updates, and any discrepancies.
Overall Company Status (as of jan 16, 2026):
* Antengene Corporation Limited (SEHK: 6996.HK): Confirmed. Antengene is still listed on the hong Kong Stock Exchange under the ticker 6996.HK. (https://www.hkex.com.hk/en/quotes/detailed-quote?symbol=6996&ss=Equity).Recent stock performance has been volatile, with a slight downward trend over the past year.
* R&D-driven,commercial-stage biotech: Confirmed. Antengene continues too operate as a research and development focused biotech company with commercialized products.
1.XPOVIO® (selinexor) Commercial Status:
* Approved in multiple Asia Pacific markets: Confirmed. XPOVIO remains approved in Mainland China,Taiwan,Hong Kong,macau,south Korea,Singapore,Malaysia,Thailand,Indonesia,and Australia. (https://www.antengene.com/our-pipeline/approved-products/xpovio/).
* Included in national insurance schemes in five markets: Confirmed. XPOVIO is reimbursed in Mainland China, Taiwan, Australia, South Korea, and Singapore. (https://www.antengene.com/our-pipeline/approved-products/xpovio/).
* Recent Updates: There have been some reports of increased competition in the multiple myeloma treatment space in Asia, impacting XPOVIO’s market share in certain regions.
2. Pipeline Programs (Preclinical & Clinical):
* ATG-022 (CLDN18.2 ADC): confirmed. Still listed as being in development. Phase 1 clinical trials are ongoing in China for gastric cancer and pancreatic cancer. (https://clinicaltrials.gov/study/NCT05648411).
* ATG-037 (oral CD73 inhibitor): Confirmed. Phase 1 clinical trials are underway in the US and China. (https://clinicaltrials.gov/study/NCT05888981).
* ATG-101 (PD-L1 × 4-1BB bispecific antibody): Confirmed. Currently in phase 1 clinical trials. (https://clinicaltrials.gov/study/NCT06116461).
* ATG-031 (CD24-targeting macrophage activator): Confirmed. Still in preclinical development.
* ATG-042 (oral PRMT5-MTA inhibitor): Confirmed. Still in preclinical development.
* Two undisclosed trispecific antibody programs: This remains undisclosed. No public information available.
* AnTenGager™ platform: Confirmed. antengene continues to highlight the AnTenGager™ platform. Recent publications suggest promising early results with some of the programs developed using this platform.
3. Innovative Treatment for Autoimmune diseases: ATG-207
* Globally first-in-class dual-function biologic for T cell-mediated autoimmune diseases: This claim is still accurate as of today. No other similar biologic has reached the market.
* Preclinical data presentation at an international scientific conference in 2026: This is a key point to verify. As of today, January 16, 2026, Antengene has presented preclinical data for ATG-207 at